vs
Side-by-side financial comparison of COMMERCE BANCSHARES INC (CBSH) and Bio-Techne (TECH). Click either name above to swap in a different company.
COMMERCE BANCSHARES INC is the larger business by last-quarter revenue ($475.7M vs $295.9M, roughly 1.6× Bio-Techne). COMMERCE BANCSHARES INC runs the higher net margin — 29.8% vs 12.8%, a 16.9% gap on every dollar of revenue. On growth, COMMERCE BANCSHARES INC posted the faster year-over-year revenue change (11.1% vs -6.4%). Over the past eight quarters, COMMERCE BANCSHARES INC's revenue compounded faster (7.1% CAGR vs 4.2%).
Commerce Bancshares, Inc. is a regional bank holding company headquartered in Missouri, with principal offices in Kansas City and St. Louis. It is the corporate parent of Commerce Bank, which offers a diversified line of financial services, including business and personal banking, wealth management and investments through its affiliated companies.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CBSH vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $475.7M | $295.9M |
| Net Profit | $141.6M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 29.8% | 12.8% |
| Revenue YoY | 11.1% | -6.4% |
| Net Profit YoY | 0.7% | 68.3% |
| EPS (diluted) | $0.96 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $475.7M | — | ||
| Q4 25 | $449.4M | $295.9M | ||
| Q3 25 | $441.0M | — | ||
| Q2 25 | $445.8M | $317.0M | ||
| Q1 25 | $428.1M | $316.2M | ||
| Q4 24 | $422.1M | $297.0M | ||
| Q3 24 | $421.4M | $289.5M | ||
| Q2 24 | $414.5M | $306.1M |
| Q1 26 | $141.6M | — | ||
| Q4 25 | $140.7M | $38.0M | ||
| Q3 25 | $141.5M | — | ||
| Q2 25 | $152.5M | $-17.7M | ||
| Q1 25 | $131.6M | $22.6M | ||
| Q4 24 | $136.1M | $34.9M | ||
| Q3 24 | $138.0M | $33.6M | ||
| Q2 24 | $139.6M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 40.8% | 18.4% | ||
| Q3 25 | 41.9% | — | ||
| Q2 25 | 44.0% | -7.5% | ||
| Q1 25 | 39.2% | 12.2% | ||
| Q4 24 | 41.2% | 16.0% | ||
| Q3 24 | 42.4% | 13.8% | ||
| Q2 24 | 43.4% | 15.0% |
| Q1 26 | 29.8% | — | ||
| Q4 25 | 31.3% | 12.8% | ||
| Q3 25 | 32.1% | — | ||
| Q2 25 | 34.2% | -5.6% | ||
| Q1 25 | 30.7% | 7.1% | ||
| Q4 24 | 32.2% | 11.7% | ||
| Q3 24 | 32.8% | 11.6% | ||
| Q2 24 | 33.7% | 13.3% |
| Q1 26 | $0.96 | — | ||
| Q4 25 | $0.86 | $0.24 | ||
| Q3 25 | $1.06 | — | ||
| Q2 25 | $1.14 | $-0.11 | ||
| Q1 25 | $0.98 | $0.14 | ||
| Q4 24 | $0.83 | $0.22 | ||
| Q3 24 | $1.01 | $0.21 | ||
| Q2 24 | $1.03 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $4.3B | $2.0B |
| Total Assets | $35.7B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $3.8B | $2.0B | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.6B | $1.9B | ||
| Q1 25 | $3.5B | $2.0B | ||
| Q4 24 | $3.3B | $2.1B | ||
| Q3 24 | $3.4B | $2.1B | ||
| Q2 24 | $3.1B | $2.1B |
| Q1 26 | $35.7B | — | ||
| Q4 25 | $32.9B | $2.5B | ||
| Q3 25 | $32.3B | — | ||
| Q2 25 | $32.3B | $2.6B | ||
| Q1 25 | $32.4B | $2.6B | ||
| Q4 24 | $32.0B | $2.7B | ||
| Q3 24 | $31.5B | $2.7B | ||
| Q2 24 | $30.6B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBSH
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
